Alfano L, James M, Grosfjeld Petersen K, Rudolf K, Vissing J, Augsburger R
Ann Clin Transl Neurol. 2024; 12(2):332-344.
PMID: 39675022
PMC: 11822816.
DOI: 10.1002/acn3.52276.
Ugur F, Gurbuz I, Koken O, Citak Kurt A, Yilmaz O
Rev Assoc Med Bras (1992). 2024; 70(12):e20241109.
PMID: 39630734
PMC: 11639577.
DOI: 10.1590/1806-9282.20241109.
Muntoni F, Goemans N, Posner N, Signorovitch J, Johnson M, He C
PLoS One. 2024; 19(10):e0307118.
PMID: 39475941
PMC: 11524485.
DOI: 10.1371/journal.pone.0307118.
Harper A, Topaloglu H, Mercuri E, Suslov V, Wu L, Ayanoglu C
Sci Rep. 2024; 14(1):23488.
PMID: 39379403
PMC: 11461856.
DOI: 10.1038/s41598-024-70783-y.
Benemei S, Gatto F, Boni L, Pane M
Acta Neurol Belg. 2024; 125(1):1-12.
PMID: 39080230
PMC: 11876273.
DOI: 10.1007/s13760-024-02600-2.
Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy.
Foley A, Yun P, Leach M, Neuhaus S, Averion G, Hu Y
Neurol Genet. 2024; 10(3):e200148.
PMID: 38915423
PMC: 11139016.
DOI: 10.1212/NXG.0000000000200148.
Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.
McDonald C, Signorovitch J, Mercuri E, Niks E, Wong B, Fillbrunn M
PLoS One. 2024; 19(6):e0304099.
PMID: 38829874
PMC: 11146704.
DOI: 10.1371/journal.pone.0304099.
Relationship Between Hand Strength and Function in Duchenne Muscular Dystrophy and Spinal Muscular Atrophy: Implications for Clinical Trials.
Decostre V, Antonio M, Servais L, Hogrel J
J Neuromuscul Dis. 2024; 11(4):777-790.
PMID: 38788084
PMC: 11307056.
DOI: 10.3233/JND-230182.
Validity of the Functional Classification of the Upper Extremities for Duchenne Muscular Dystrophy.
Miyazaki Y, Hara T, Hagiwara K, Nakamura T, Kamimura A, Takeshita E
Prog Rehabil Med. 2024; 9:20240016.
PMID: 38665904
PMC: 11040242.
DOI: 10.2490/prm.20240016.
Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.
Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews K
BMC Neurol. 2024; 24(1):96.
PMID: 38491364
PMC: 10941356.
DOI: 10.1186/s12883-024-03588-1.
Continuitiy of care with ataluren in Duchenne Muscular Dystrophy patients with nonsense mutations after loss of ambulation. Personal experience.
Spagnoli C, Adorisio R, Bello L, DAmico A, DAngelo M, Pane M
Acta Myol. 2024; 42(4):118-122.
PMID: 38406379
PMC: 10883323.
DOI: 10.36185/2532-1900-396.
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.
McDonald C, Camino E, Escandon R, Finkel R, Fischer R, Flanigan K
J Neuromuscul Dis. 2024; 11(2):499-523.
PMID: 38363616
PMC: 10977441.
DOI: 10.3233/JND-230219.
Design requirements of upper extremity supports for daily use in Duchenne muscular dystrophy with severe muscle weakness.
Filius S, Harlaar J, Alberts L, Houwen-van Opstal S, van der Kooij H, Janssen M
J Rehabil Assist Technol Eng. 2024; 11:20556683241228478.
PMID: 38344392
PMC: 10854382.
DOI: 10.1177/20556683241228478.
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Niezgoda A, Bieganski G, Wachowiak J, Czarnota J, Siemionow K, Heydemann A
Arch Immunol Ther Exp (Warsz). 2023; 71(1):24.
PMID: 37999748
PMC: 10673998.
DOI: 10.1007/s00005-023-00691-y.
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy: A GRASP-LGMD study.
Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews K
Res Sq. 2023; .
PMID: 37886601
PMC: 10602119.
DOI: 10.21203/rs.3.rs-3370395/v1.
Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.
Ishizuka T, Komaki H, Asahina Y, Nakamura H, Motohashi N, Takeshita E
Neuropsychopharmacol Rep. 2023; 43(2):277-286.
PMID: 37326950
PMC: 10275280.
DOI: 10.1002/npr2.12335.
Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?.
Bello L, Hoffman E, Pegoraro E
Nat Rev Neurol. 2023; 19(7):410-423.
PMID: 37308617
DOI: 10.1038/s41582-023-00823-0.
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
Connolly A, Zaidman C, Brandsema J, Phan H, Tian C, Zhang X
J Neuromuscul Dis. 2023; 10(4):685-699.
PMID: 37248912
PMC: 10357134.
DOI: 10.3233/JND-230019.
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study.
Brogna C, Pane M, Coratti G, DAmico A, Pegoraro E, Bello L
Children (Basel). 2023; 10(4).
PMID: 37189996
PMC: 10136754.
DOI: 10.3390/children10040746.
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?.
Pane M, Coratti G, Brogna C, Bovis F, DAmico A, Pegoraro E
J Neuromuscul Dis. 2023; 10(4):567-574.
PMID: 37066919
PMC: 10357219.
DOI: 10.3233/JND-221556.